SELLAS Life Sciences Group, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
SELLAS Life Sciences Group, Inc. (SLS) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$16.76 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2021-03-23
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$3.72M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$4.47M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$4.42M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$4.14M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$16.76M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was -$19.29M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was -$27.67M.
- SELLAS Life Sciences Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was -$23.75M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$8.19M derived: sum of 2 quarters · filed 2021-03-23 | -$12.61M derived: sum of 3 quarters · filed 2021-03-23 | -$16.76M 10-K · filed 2021-03-23 | |||
| 2020-09-30 | -$4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$8.90M derived: sum of 2 quarters · filed 2020-11-13 | -$13.04M 10-Q · filed 2020-11-13 | -$20.46M derived: sum of 4 quarters · filed 2021-03-23 | |||
| 2020-06-30 | -$4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$8.57M 10-Q · filed 2020-08-13 | -$15.99M derived: sum of 3 quarters · filed 2021-03-23 | -$20.19M derived: sum of 4 quarters · filed 2021-03-23 | |||
| 2020-03-31 | -$4.14M 10-Q · filed 2020-05-14 | -$11.56M derived: sum of 2 quarters · filed 2021-03-23 | -$15.76M derived: sum of 3 quarters · filed 2021-03-23 | -$18.90M derived: sum of 4 quarters · filed 2021-03-23 | |||
| 2019-12-31 | -$7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$11.62M derived: sum of 2 quarters · filed 2021-03-23 | -$14.76M derived: sum of 3 quarters · filed 2021-03-23 | -$19.29M 10-K · filed 2021-03-23 | |||
| 2019-09-30 | -$4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$7.34M derived: sum of 2 quarters · filed 2020-11-13 | -$11.87M 10-Q · filed 2020-11-13 | -$25.20M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | -$3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$7.67M 10-Q · filed 2020-08-13 | -$20.99M derived: sum of 3 quarters · filed 2020-08-13 | -$21.28M derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2019-03-31 | -$4.54M 10-Q · filed 2020-05-14 | -$17.86M derived: sum of 2 quarters · filed 2020-05-14 | -$18.15M derived: sum of 3 quarters · filed 2020-05-14 | -$24.21M derived: sum of 4 quarters · filed 2020-05-14 | |||
| 2018-12-31 | -$13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$13.61M derived: sum of 2 quarters · filed 2020-03-13 | -$19.68M derived: sum of 3 quarters · filed 2020-03-13 | -$27.67M 10-K · filed 2020-03-13 | |||
| 2018-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$6.35M derived: sum of 2 quarters · filed 2019-11-14 | -$14.35M 10-Q · filed 2019-11-14 | -$23.13M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | -$6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$14.06M 10-Q · filed 2019-08-14 | -$22.84M derived: sum of 3 quarters · filed 2019-08-14 | -$29.04M derived: sum of 4 quarters · filed 2019-08-14 | |||
| 2018-03-31 | -$8.00M 10-Q · filed 2019-05-15 | -$16.78M derived: sum of 2 quarters · filed 2019-05-15 | -$22.97M derived: sum of 3 quarters · filed 2019-05-15 | -$30.07M derived: sum of 4 quarters · filed 2019-05-15 | |||
| 2017-12-31 | -$8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$14.98M derived: sum of 2 quarters · filed 2019-03-22 | -$22.08M derived: sum of 3 quarters · filed 2019-03-22 | -$23.75M 10-K · filed 2019-03-22 | |||
| 2017-09-30 | -$6.19M 10-Q · filed 2017-11-09 | -$13.29M derived: sum of 2 quarters · filed 2017-11-09 | -$14.97M 10-Q · filed 2018-11-14 | -$15.58M 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | -$7.10M 10-Q · filed 2017-08-14 | -$10.51M 10-Q · filed 2018-08-14 | -$9.38M 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | -$4.60M 10-Q · filed 2018-05-15 | -$2.28M 10-Q · filed 2017-05-10 | |||||
| 2016-09-30 | -$4.34M 10-Q · filed 2017-11-09 | $3.94M derived: sum of 2 quarters · filed 2017-11-09 | -$9.17M 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | $8.28M 10-Q · filed 2017-08-14 | -$4.82M 10-Q · filed 2017-08-14 | |||||
| 2016-03-31 | -$13.10M 10-Q · filed 2017-05-10 | ||||||
| 2015-09-30 | -$6.35M 10-Q · filed 2016-11-09 | -$19.83M derived: sum of 2 quarters · filed 2016-11-09 | -$28.15M 10-Q · filed 2016-11-09 | ||||
| 2015-06-30 | -$13.47M 10-Q · filed 2016-08-09 | -$21.78M 10-Q · filed 2016-08-09 | |||||
| 2015-03-31 | -$8.31M 10-Q · filed 2016-05-10 | ||||||
| 2014-09-30 | -$3.53M 10-Q · filed 2015-11-09 | -$22.02M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |